Concepedia

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

Bojana Milojkovic Kerklaan, S. Slater, Michael Flynn, Alastair Greystoke, Petronella O. Witteveen, M. Megui-Roelvink, Filip De Vos, Emma Dean, Larisa Reyderman, Lone H. Ottesen,

Investigational New Drugs · 2016 · 32 citations · 13 references

DOI

Concepts

References

13

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp, Monika E. Hegi, Thierry Gorlia et al. · The Lancet Oncology · 2014 · 1K citations

, , +14

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

Roger Stupp, Monika E. Hegi, Bart Neyns et al. · Journal of Clinical Oncology · 2010 · 443 citations · Full text

, , +16

Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours

M. Cianfrocca, Kathryn A. Kimmel, James M. Gallo et al. · British Journal of Cancer · 2006 · 177 citations · Full text

, , +15

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma

David A. Reardon, Morris D. Groves, Patrick Y. Wen et al. · Clinical Cancer Research · 2013 · 126 citations

, , +15

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma

Steven O’Day, Anna C. Pavlick, Carmen Loquai et al. · British Journal of Cancer · 2011 · 118 citations · Full text

, , +16